Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Article Details
- CitationCopy to clipboard
Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Pharm World Sci. 1997 Aug;19(4):159-75.
- PubMed ID
- 9297727 [ View in PubMed]
- Abstract
In this review the clinical pharmacology of HIV protease inhibitors, a new class of antiretroviral drugs, is discussed. After considering HIV protease function and structure, the development of inhibitors of HIV protease is presented. Three protease inhibitors are reviewed in more detail: saquinavir, indinavir, and ritonavir. Clinical trial results with these agents are evaluated. Furthermore, adverse effects, resistance, dosage and administration, clinical pharmacokinetics, pharmacokinetic-pharmacodynamic relationships, and drug interactions are discussed.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Indinavir Human immunodeficiency virus type 1 protease Protein Human immunodeficiency virus 1 YesInhibitorDetails Ritonavir Human immunodeficiency virus type 1 protease Protein Human immunodeficiency virus 1 YesInhibitorDetails Saquinavir Human immunodeficiency virus type 1 protease Protein Human immunodeficiency virus 1 YesInhibitorDetails